Helping You Reach the Clinic Faster

Gene-to-GMP-Reverse-logo-800.png

With GENE to GMP™ we can help you achieve faster time-to-market, lower manufacturing costs and can rescue your promising drug candidates.

Selexis SA and KBI Biopharma have joined forces to provide industry partners “GENE to GMP in 9 Months” – the most robust and fastest service offering for the biopharmaceutical industry. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.

LEARN MORE

Science-Driven

Science-Driven.

KBI’s broad range of product development services, expertise in biophysical and biochemical characterization of proteins, and flexible business model make us an excellent partner. Our contract development and manufacturing services are built on a strategic cornerstone of deep analytical capabilities. We are passionate in the belief that detailed protein characterization drives speed, benefiting clients at every stage of the development and manufacturing process.

Customer-Focused

Customer-Focused.

KBI’s business model is designed from the ground up to help clients accelerate their path to market while reducing risk and building value. Our customers range from early stage biotech to global pharmaceutical companies, and also include academic/non-profit organizations. In every client testimonial we’ve received and in every client survey we’ve seen, we are proud to report that KBI is viewed as the most collaborative and responsive of all the contractors with whom our clients work. To date, we have served over 300 clients globally.

Trusted Experience

Trusted Experience.

KBI’s extensive track record of successful process development and manufacturing programs is a result of our unique approach of applying the insight gained from our advanced biophysical protein characterization methodologies, towards the development of robust and scalable processes. We deliver accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) for our clients, including numerous successful regulatory submissions.

News

Press Release | CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and Nanoparticles

Learn More